$2 Trillion Disappears Because of Fed's Secretive New Move

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Albert P L Stroucken net worth and biography

Albert Stroucken Biography and Net Worth

Director of Baxter International

Albert P.L. Stroucken has served as a director of Baxter since 2004 and was appointed lead director in February 2021.

Stroucken is former executive chairman of the board of directors of Owens-Illinois, Inc., where he also served as chairman, president, and chief executive officer from 2006 through 2015. From 1998 to 2006, Stroucken served as president and chief executive officer of H.B. Fuller Company, a manufacturer of adhesives, sealants, coatings, paints, and other specialty chemicals. He served as chairman of H.B. Fuller Company from 1999 to 2006.

From 1997 to 1998, he was general manager of the inorganics division of Bayer AG. From 1992 to 1997, Stroucken was executive vice president and president of the industrial chemicals division of Bayer Corporation. He previously served as director of Baxalta and of Shire (before it was acquired by Takeda Pharmaceutical in 2019).

What is Albert P L Stroucken's net worth?: The estimated net worth of Albert P L Stroucken is at least $1.09 million as of March 20th, 2023. Stroucken owns 36,835 shares of Baxter International stock worth more than $1,086,633 as of December 22nd. This net worth estimate does not reflect any other investments that Stroucken may own. Learn More about Albert P L Stroucken's net worth.
How do I contact Albert P L Stroucken?: The corporate mailing address for Stroucken and other Baxter International executives is One Baxter Parkway DF2-1W, Deerfield IL, 60015. Baxter International can also be reached via phone at (224) 948-2000 and via email at [email protected]. Learn More on Albert P L Stroucken's contact information.
Has Albert P L Stroucken been buying or selling shares of Baxter International?: Albert P L Stroucken has not been actively trading shares of Baxter International during the last quarter. Most recently, Albert P. L. Stroucken sold 3,930 shares of the business's stock in a transaction on Monday, March 20th. The shares were sold at an average price of $37.52, for a transaction totalling $147,453.60. Following the completion of the sale, the director now directly owns 36,835 shares of the company's stock, valued at $1,382,049.20. Learn More on Albert P L Stroucken's trading history.
Who are Baxter International's active insiders?: Baxter International's insider roster includes Giuseppe Accogli (SVP), John Forsyth (Director), Andrew Frye (SVP), James Gavin, III (Director), Jacqueline Kunzler (SVP), Sean Martin (SVP), Jeanne Mason (SVP), Brian Stevens (CAO), and Albert Stroucken (Director). Learn More on Baxter International's active insiders.

Albert P L Stroucken Insider Trading History at Baxter International

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/20/2023	Sell	3,930	$37.52	$147,453.60	36,835
4/5/2022	Sell	4,020	$76.02	$305,600.40	27,629
4/5/2021	Sell	4,990	$84.56	$421,954.40	36,886
4/1/2020	Sell	4,320	$79.64	$344,044.80	34,018
4/10/2017	Sell	4,280	$52.80	$225,984.00	25,667

Albert P L Stroucken Buying and Selling Activity at Baxter International

Baxter International Company Overview

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Today's Range

Now: $29.50

$29.17

$29.99

50 Day Range

MA: $33.70

$28.90

$36.91

2 Week Range

Now: $29.50

$28.62

$44.01

Volume

12,194,859 shs

Average Volume

4,174,975 shs

Market Capitalization

$15.06 billion

P/E Ratio

147.51

Dividend Yield

2.35%

Beta

0.58